NCT06195371Not yet recruiting
Impact of CASP3 Gene in Chemoresistance
The Impact of CASP3 Gene in Chemoresistant Breast Cancer
Source: ClinicalTrials.gov · Last updated 28 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. This study aims to evaluate the abnormalities of CASP3 gene in chemo resistance in breast cancer by FISH technique. evaluate the abnormalities of CASP3 gene in chemo resistance in breast cancer by FISH technique. 2. Detect CASP3 gene abnormality relation to survival, chemoresponse \& chemoresistance. 3. Correlate CASP3 gene abnormalities with available clinicopathological data of breast cancer patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 23 Dec 2023
- Start date
- 1 May 2024
- Primary completion date
- Nov 2026
- Lead sponsor
- Gehad Salah El-Din shaker
- Diseases
- Childhood cancers
- NCT number
- NCT06195371
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 May 2024 to the primary completion date, Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other malignant diseases-Male breast cancer .
Who the study is looking for
- Newly diagnosed patients of breast cancer admitted to South Egypt Cancer Institute at different stages of the disease
Age in the registry: 15 years to 75 years · Sex: Female
This page is information, not medical advice. Discuss any trial with your doctor.